Moleculin Biotech Inc. Financials
MBRX
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM ~6.5:1 split | DEC 2025 ~23.7:1 split | DEC 2024 ~1.5:1 split | DEC 2023 | DEC 2022 | DEC 2021 ~2.7:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| General & Administrative | $9 | $9 | $9 | $10 | $12 | $8 |
| Research & Development | $20 | $16 | $18 | $19 | $19 | $14 |
| Total Operating Expenses | $30 | $25 | $27 | $30 | $31 | $23 |
| Operating Income | -$30 | -$25 | -$27 | -$30 | -$31 | -$23 |
| Other Non-Operating Income (Expense) | $0 | -$0 | $0 | $0 | $0 | $0 |
| EBT (Earnings Before Tax) | – | -$34 | -$26 | – | – | – |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$11 | -$34 | -$26 | -$30 | -$29 | -$16 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Basic) | $553.64 | -$568.40 | -$3,782.80 | -$7,535.00 | -$7,610.00 | -$4,425.00 |
| EPS (Diluted) | $474.64 | -$209.80 | -$3,854.51 | -$6,682.11 | -$114,060.72 | -$4,435.38 |
| Weighted Avg Shares (Basic) | 757,858 | 1.2M | 3.4M | 2.0M | 28.6M | 26.9M |
| Weighted Avg Shares (Diluted) | – | – | – | – | – | 26.9M |
| Shares Outstanding | 1.0M | 159,961.4 | 6,757.79 | 4,455.032 | 3,817.046 | 3,583.457 |
Moleculin Biotech (MBRX) financials: revenue, profit and margins
Moleculin Biotech (MBRX) generated about $0.00 in revenue and -$11 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Moleculin Biotech's (MBRX) revenue?+
Moleculin Biotech generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Moleculin Biotech profitable?+
Moleculin Biotech reported about -$11 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 6 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 13 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with MBRX
Spot a number that looks wrong? Check it in MBRX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MBRX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.